<HTML xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki  ltr ns-0 ns-subject page-Team_Freiburg_Bioware_Project_Targeting_Fusion"><DIV id="globalWrapper"><DIV id="top-section"><DIV id="p-logo"><A href="/Main_Page" title="Main Page">&quot;
	    </A></DIV><DIV id="menubar" class="left-menu noprint"><UL><LI class="selected"><A href="/Team:Freiburg_Bioware/Project/Targeting_Fusion">Page               </A></LI><LI class="new"><A href="/wiki/index.php?title=Talk:Team:Freiburg_Bioware/Project/Targeting_Fusion&amp;action=edit&amp;redlink=1">Discussion               </A></LI><LI><A href="/wiki/index.php?title=Team:Freiburg_Bioware/Project/Targeting_Fusion&amp;action=edit">View source               </A></LI><LI><A href="/wiki/index.php?title=Team:Freiburg_Bioware/Project/Targeting_Fusion&amp;action=history">History               </A></LI><LI style="color:#808080;cursor:default">teams</LI></UL></DIV><DIV class="right-menu noprint" id="menubar"><UL><LI id="pt-login"><A href="/wiki/index.php?title=Special:UserLogin&amp;returnto=Team:Freiburg_Bioware/Project/Targeting_Fusion" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o">Log in</A></LI></UL></DIV><DIV id="search-controls" class="noprint"><FORM action="/Special:Search" id="searchform"> </FORM></DIV></DIV><DIV id="content"><H1 class="firstHeading">Team:Freiburg Bioware/Project/Targeting Fusion</H1><DIV id="bodyContent"><H3 id="siteSub" class="noprint">From 2010.igem.org</H3><DIV id="menu"><UL id="menu"><LI><DL><DT class="menu_button_left"><A href="https://2010.igem.org/Team:Freiburg_Bioware">Home</A></DT></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Team_2010">Team</A></DT><DD class="first"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Team_2010">Team 2010</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Collaboration">Collaboration</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Cuckoo_Clock">Cuckoo Clock Competition</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Photo_Gallery">Photo Gallery</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Statistics">Statistics</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Team/Contribution">Contribution</A></DD></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#highlights">Project</A></DT><DD class="first"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results">Summary</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#highlights">Highlights</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Project_Description">Introduction</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results">Results</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#modularization">   Modularization</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#targeting">   Targeting</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#arming">   Arming</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Results#superconstruct">   Tumor Killing</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling">   Modeling</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Methods">Methods</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Virus_Construction_Kit">Virus Construction Kit Manual</A></DD></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/BioBricks">BioBricks</A></DT><DD class="first"><A href="https://2010.igem.org/Team:Freiburg_Bioware/BioBricks">Overview</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/BioBricks/capsid_coding">Capsid Coding Parts</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/BioBricks/vector_plasmid">Vector Plasmid Parts</A></DD></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Notebook">Notebook</A></DT><DD class="first"><A href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Labjournal">Labjournal</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Materials">Cloning Material</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Project/Methods">Methods</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Meetings">Meetings</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/NoteBook/Statistics">Statistics</A></DD></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Sponsors">Sponsors</A></DT></DL></LI><LI><DL><DT class="menu_button_center"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Safety">Safety</A></DT></DL></LI><LI><DL><DT class="menu_button_right"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling">Modeling</A></DT><DD class="first"><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling">Modeling Overview</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling/Virus_Production">Virus Production</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling/Virus_Infection">Virus Infection</A></DD><DD><A href="https://2010.igem.org/Team:Freiburg_Bioware/Modeling/Structure_Modeling">Structure Modeling</A></DD></DL></LI></UL></DIV><DIV class="pageContent"><P class="MsoToc2"><SPAN lang="DE"><A href="#_Toc275953546"><SPAN lang="EN-US">Tumor
Targeting by N-terminal Fusion to Virus Capsid
</SPAN></A></SPAN></P><P class="MsoToc3"><SPAN lang="DE"><A href="#_Toc275953547"><SPAN lang="EN-US">Design</SPAN></A></SPAN></P><P class="MsoToc4"><SPAN lang="DE"><A href="#_Toc275953548"><SPAN lang="EN-US">VP2
Fusion</SPAN></A></SPAN></P><P class="MsoToc4"><SPAN lang="DE"><A href="#_Toc275953549"><SPAN lang="EN-US">VP1
Insertion</SPAN></A></SPAN></P><P class="MsoToc3"><SPAN lang="DE"><A href="#_Toc275953550"><SPAN lang="EN-US">Cloning
Verified by Colony PCR</SPAN></A></SPAN></P><P class="MsoToc3"><SPAN lang="DE"><A href="#_Toc275953551"><SPAN lang="EN-US">Fluorescence
Analysis of Viral Stocks</SPAN></A></SPAN></P><P class="MsoToc3"><SPAN lang="DE"><A href="#_Toc275953552"><SPAN lang="EN-US">Concentrating
VP1UP_NLS_mVenus_VP2/3 Viruses</SPAN></A></SPAN></P><P class="MsoToc3"><SPAN lang="DE"><A href="#_Toc275953553"><SPAN lang="EN-US">Nuclear
Localization by Fluorescence Microscopy</SPAN></A></SPAN></P><P class="MsoToc3"><SPAN lang="DE"><A href="#_Toc275953554"><SPAN lang="EN-US">Transduction
Efficacy by Flow Cytometry</SPAN></A></SPAN></P><P class="MsoToc3"><SPAN lang="DE"><A href="#_Toc275953555"><SPAN lang="EN-US">Infectious
Titer by qPCR</SPAN></A></SPAN></P><P class="MsoToc3"><SPAN lang="DE"><A href="#_Toc275953556"><SPAN lang="EN-US">Killing
cells: Time-Lapse</SPAN></A></SPAN></P><P class="MsoNormal"> </P><P class="MsoNormal"> </P><H2><A name="_Toc275953546">Tumor Targeting by
N-terminal Fusion to Virus Capsid
</A></H2><H3><A name="_Toc275953547">Design</A></H3><H4><A name="_Toc275953548">VP2 Fusion</A></H4><P class="MsoNormal">The Freiburg2010 team fused motifs
which are desired to be
surface exposed to the N-terminus of VP2/3 open reading frame, avoiding
steric
hindrance by connecting them with linker. We ensured in frame coupling
by
designing or using the referring parts in the Freiburg RFC25 standard,
thus
creating fusion constructs via NgoMIV and AgeI. For retargeting AAV2
virus
particles towards EGFR over expressing cancer cells we investigated the
Z<SUB>EGFR:1907</SUB>
Affibody and the E01 DARPin – in combination with VP2/3_587-KO (HSPG
knock
down) – as surface exposed motifs. We also created so called
“all-in-one” virus
particles by fusing VP2/3_His-Tag or VP2/3_BAP via Middle Linker to the
Affibody. Purification or imaging approaches could be conducted by
His-Tag or
CFP motifs, respectively. All constructs were cloned downstream of the
CMV
promoter (Fig.1).</P><P class="MsoNormal"><B>Table 1: List of VP2 fusion
parts</B></P><P class="MsoNormal">  </P><P class="MsoNormal"><B>Figure 1: Cloning scheme of
VP2 fusion</B></P><P class="MsoNormal">First of all we fused the Affibody
ZEGFR:1907 to the Short-,
Middle-, Long- or SEG Linker and cloned the resulting constructs
downstream of the
CMV promoter. Afterwards either unmodified VP2/3 or HSPG affinity knock
down
VP2/3 were fused to the different linkers. Further on CFP and His-Tag
were
coupled to VP2/3 by the Middle Linker (Fig. 2).</P><P class="MsoNormal" style="line-height: normal;"><SPAN style=""><SPAN style=""> </SPAN></SPAN><B style=""><SPAN style="font-size: 10pt;">Figure
2:</SPAN></B><SPAN style="font-size: 10pt;">
Agarose Gel Electrophoresis.
Fusion of VP2/3 to CMV_Affibody_Linker or CMV_CFP_MiddleLinker
constructs.</SPAN></P><P class="MsoNormal">We conducted three fragment ligations
with the DARPin E01,
MiddleLinker_VP2/3 or MiddleLinker_VP2/3(587KO) and pSB1C3_CMV plasmid
(Fig.
3).</P><P style="text-align: center;" class="MsoNormal"> </P><P class="MsoNormal" style="line-height: normal;"><B style=""><SPAN style="font-size: 10pt;">Figure
3:</SPAN></B><SPAN style="font-size: 10pt;">
Agarose Gel Electrophoresis. <B style="">A)</B>
Three fragment ligation of DARPin
fused to N-terminus of VP2/3. <B style="">B)</B>
Test digestion verified successful cloning.</SPAN></P><P class="MsoNormal">For 100 % replacement of wildtype VP2
the fusion plasmid was
co-transfected to the Rep/Cap plasmid which contained a start codon
mutation of
VP2. Wildtype VP2 knock-out was achieved by site-directed mutagenesis
(Fig. 4).
</P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 200%;">Figure 4:
Knock out of VP2</SPAN></B> in the Cap coding region of
Rep/Cap plasmid:
Knock-out of start codon via site-directed mutagenesis (note the C in
the sequence).</P><P class="MsoNormal"> </P><H4><A name="_Toc275953549">VP1 Insertion</A></H4><P class="MsoNormal">We inserted three diffent motifs into
the VP1 open reading
frame. They were fused, together with the unique uspstream region of
VP1
(VP1up) and a nuclear localization sequence (NLS), according to the
RFC25
standard to VP2/3 (Fig. 2). Again, all of these parts were driven by
CMV
promoter.</P><P class="MsoNormal"><B>Table 2: List of VP1
insertion parts</B></P><P style="font-weight: bold;" class="MsoNormal">Figure
5: Cloning scheme of VP1
insertion</P><P class="MsoNormal">First VP1up-NLS was fused to the
surface exposed motif –
Affibody, His-Tag or mVenus – and the resulting constructs were cloned
downstream of the CMV promoter. This was followed by either fusing
unmodified
VP2/3 or HSPG affinity knock down VP2/3 (Fig. 6) to the different kinds
of
motifs.</P><P class="MsoNormal" style="line-height: normal;"><B style=""><SPAN style="font-size: 10pt;">Figure
6:
Agarose Gel Electrophoresis.</SPAN></B><SPAN style="font-size: 10pt;"> Fusion of VP2/3(587KO) to
pCMV_VP1up_NLS_ZEGFR:1907,
pCMV_VP1up_NLS_6xHis or pCMV_VP1up_NLS_mVenus</SPAN></P><P class="MsoNormal">We designed site-directed mutagenesis
primer for the VP1
start codon modification in the Rep/Cap plasmid in order to ensure 100
%
replacement with modified VP1 proteins (Fig. 7).</P><P style="text-align: center;" class="MsoNormal"> </P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 200%;">Figure 7:
Knock out of VP1</SPAN></B> in Cap coding region of Rep/Cap
plasmid: Knock-out
of start codon via site-directed mutagenesis.</P><P class="MsoNormal"> </P><H3><A name="_Toc275953550">Cloning Verified by
Colony PCR</A></H3><P class="MsoNormal">Big amounts of samples necessitated
fast and exact analysis
of cloning. For this purpose colony PCR was conducted. We verified
successful
VP2/3 fusion by using primer that exclusively bound to a specific
location in
the VP2/3 sequence (Fig. 8). In the case of successful ligation a 880
bp
fragment was amplified via Taq polymerase.</P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 200%;">Figure 8:</SPAN></B>
Primer Cap 3500 for and VP 4200 rev. Colony PCR using these primer
results in a
880 bp fragment</P><P class="MsoNormal"> </P><P class="MsoNormal">Figure 9 demonstrates a colony PCR
example: VP2 fusion
constructs containing VP2/3(587) sequence and the so called “All in
One”
constructs were cloned into pSB1C3_CMV. Successful cloning could be
verified
(positive control: pAAV_RC; negative control: pSB1C3_lITR).</P><P class="MsoNormal" style="line-height: normal;"><B style=""><SPAN style="font-size: 10pt;">Figure
9: Colony
PCR</SPAN></B><SPAN style="font-size: 10pt;">
of VP2
N-terminal fusion (Affibody_Linker, CFP_MiddleLinker,
His-Tag_MiddleLinker:
samples 1 - 6) and “All-in-One” constructs (samples 7 – 10).</SPAN></P><P class="MsoNormal"> </P><H3><A name="_Toc275953551">Fluorescence Analysis of
Viral Stocks</A></H3><P class="MsoNormal">We wanted to develop a protocol for
harvesting as much
viruses as possible. For this purpose we took advantage of viruses
containing
mVenus fused to VP1. In order to find out whether most viruses were
located in
the cell pellet, cell suspensions were centrifuged at 10.000 g or
20.000 g.
Afterwards mVenus fluorescence was measured at 526 nm. The resulting
values were
compared to cell culture supernatant, 20.000 g centrifuged supernatant
and
resuspended cell pellet (Fig. 10).</P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 200%;">Figure
10: Fluorescence signal of mVenus at 526 nm</SPAN></B>,
inserted into the virus
capsid. Transduced cells were resuspended, pelleted or supernatant was
taken in
order to determine the location of most viruses. Control: DMEM.</P><P class="MsoNormal"> </P><H3><A name="_Toc275953552">Concentrating
VP1UP_NLS_mVenus_VP2/3 Viruses</A></H3><P class="MsoNormal">For further analysis, viral stocks
originating from cell
culture supernatant needed to be concentrated. Therefore
ultrafiltration with
protein concentrators (Sartorius VivaSpin 20; 20.000Da MWCO) was
conducted.
Figure 11 shows fluorescence microscopy image of an aliquot from
ultrafiltrated
cell culture supernatant / cell lysate containing
VP1up_NLS_mVenus_VP2/3
viruses.</P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 200%;">Figure
11: Fluorescence Microscopy</SPAN></B>. A) Brightfield
picture of an aliquot of
concentrated VP1up_NLS_mVenus_VP2/3 containing virus stock. B) At 505
nm
excitation mVenus fluorescence of the virus particles could be
detected. C)
Merged image</P><P class="MsoNormal"> </P><H3><A name="_Toc275953553">Nuclear Localization by
Fluorescence Microscopy</A></H3><P class="MsoNormal">AAV-293 cells were transfected with a
50:50 ratio of the
Rep/Cap(VP1KO) to the CMV_VP1_NLS_mVenus_VP2/3 plasmid. We packaged
mCherry,
driven by the CMV promoter, into the virus capsids and followed protein
expression
via fluorescence microscopy. 30 hours post transfection mCherry
fluorescence
was detectable in the whole cytosol of the successfully transfected
cells,
demonstrating that DNA located between the AAV2 ITRs is already
transcribed in
the producer cell line. In contrast to that mVenus fluorescence signal
could be
observed only in the nuclei (Fig. 12). This indicated that the nuclear
localization sequence targets the single VP1_NLS_mVenus_VP2/3 proteins
efficiently to the cell nucleus, where assembly and packaging of the
virus
particles takes place. </P><P class="MsoNormal" style="line-height: normal;"> <B style=""><SPAN style="font-size: 10pt;">Figure
12:
Fluorescence Microscopy. A) </SPAN></B><SPAN style="font-size: 10pt;">Brightfiled picture. <B style="">B)</B>
Excitation at 555 nm showed mCherry signal in the cytosol. <B style="">C)</B> Excitation at 505 nm revealed mVenus
fluorescence in the nuclei, indicating functionality of the nuclear
localization sequence inserted – together with mVenus – into VP1. <B style="">D)</B> Merged image.</SPAN></P><H3><A name="_Toc275953554">Transduction Efficacy by
Flow Cytometry</A></H3><P class="MsoNormal">For determination of transduction
efficacy flow cytometry
analysis was conducted. The Affibody Z<SUB><SPAN style="font-size: 12pt; line-height: 200%;">EGFR:1907</SPAN></SUB>
was fused with SEG-, middle- and long
linker to the VP2/3 open reading frame (ORF) in order to investigate
differences in infection efficacy due to different linker lengths.
250.000
AAV-293 cells were transfected with 1 µg total DNA. Different ratios of
VP2
fusion constructs in respect to the Rep/Cap plasmid were
co-transfected. 72
hours post transfection viruses were harvested and two different cell
lines,
HT1080 and A431, were transduced with 1 mL virus stock. By
encapsulating mVenus
coding sequence, the amount of transduced cells could be determined via
flow
cytometry.</P><P class="MsoNormal" style="line-height: normal;"><B style=""><SPAN style="">Figure 13: Flow
cytometry.</SPAN></B><SPAN style=""> Test of
transduction efficiency with HT1080
and A431 cells by detecting mVenus expression from <B style="">Z<SUB>EGFR:1907</SUB>_<SPAN style="">Middlelinker</SPAN>_VP2/3</B>
virus particles (Transfection ratio: 50:50 in respect to Rep/Cap
plasmid). A) Gating
non transduced cells (control); subcellular debris and cellular
aggregates can
be distinguished from single cells by size, estimated via forward
scatter (FS
Lin) and granularity, estimated via side scatter (SS Lin). B) <B>:</B>
Non
transduced cells plotted against mVenus fluorescence (Analytical gate
was set
such that 1% or fewer of negative control cells fell within the
positive region
(R6). C) Gating transduced cells. D) Transduced cells plotted against
mVenus
fluorescence, R10 comprised transduced, mVenus expressing cells. E)
Overlay of
non-transduced (red) and transduced (green) cells plotted against
mVenus
fluorescence.</SPAN></P><P class="MsoNormal" style="line-height: normal;"><B style=""><SPAN style="">Figure 14: Flow
cytometry.</SPAN></B><SPAN style="">
Investigating transduction efficiency with
HT1080 and A431 cells by detecting mVenus expression from <B>Z<SUB>EGFR:1907</SUB>_SEG_VP2/3</B>
virus particles (Transfection ratio: 50:50 in respect to Rep/Cap
plasmid). A) Gating
non transduced cells (control); subcellular debris and cellular
aggregates can
be distinguished from single cells by size, estimated via forward
scatter (FS
Lin) and granularity, estimated via side scatter (SS Lin). B) <B>:</B>
Non
transduced cells plotted against mVenus fluorescence (Analytical gate
was set
such that 1% or fewer of negative control cells fell within the
positive region
(R6). C) Gating transduced cells. D) Transduced cells plotted against
mVenus
fluorescence, R10 comprised transduced, mVenus expressing cells. E)
Overlay of
non-transduced (red) and transduced (green) cells plotted against
mVenus
fluorescence.</SPAN></P><P class="MsoNormal" style="line-height: normal;"><B style=""><SPAN style="">Figure 15: Flow
cytometry.</SPAN></B><SPAN style="">
Investigating transduction efficiency with HT1080
and A431 cells by detecting mVenus expression from <B style="">Z<SUB>EGFR:1907</SUB>_<SPAN style="">LongLinker</SPAN>_VP2/3</B>
virus particles (Transfection ratio: 50:50 in respect to Rep/Cap
plasmid). A) Gating
non transduced cells (control); subcellular debris and cellular
aggregates can
be distinguished from single cells by size, estimated via forward
scatter (FS
Lin) and granularity, estimated via side scatter (SS Lin). B) <B>:</B>
Non
transduced cells plotted against mVenus fluorescence (Analytical gate
was set
such that 1% or fewer of negative control cells fell within the
positive region
(R6). C) Gating transduced cells. D) Transduced cells plotted against
mVenus
fluorescence, R10 comprised transduced, mVenus expressing cells. E)
Overlay of
non transduced (red) and transduced (green) cells plotted against
mVenus
fluorescence.</SPAN></P><P class="MsoNormal">Additionally viruses containing a
His-Tag or CFP, fused via
Middle Linker to the VP2/3 ORF, were analyzed. Figure 16 overviews
transduction
efficacy of all constructs, transfected in a 10:90, 25:75 and 50:50
ratio in
respect to Rep/Cap plasmid.  </P><P style="text-align: center;" class="MsoNormal"> </P><P class="MsoNormal"><B>Figure 16: Flow cytometry
analysis</B>. Transduced and
therefore mVenus positive HT1080 and A431 cells, infected with virus
particles
consisting of different ratios of VP2 fusion constructs in respect to
Rep/Cap
plasmid. </P><P class="MsoNormal"> </P><P class="MsoNormal">Transduction of HT1080 cells revealed
that all viral
particles regardless of which motifs inserted into the capsids remained
infectious with efficacies up to 85 %. In general the amount of mVenus
positive
cells decreased only slightly when harboring more modified VP2
subunits. This
indicates that larger peptides could be inserted into the AAV2 capsids
without
affecting virus assembly and packaging. A431 cells, which overexpress
EGF
receptor, were generally transduced with reduced efficacy. </P><P class="MsoNormal">Further on the Affibody Z<SUB><SPAN style="font-size: 12pt; line-height: 200%;">EGFR:1907</SPAN></SUB>
or mVenus were inserted into the VP1
ORF together with a nuclear localization signal. 250.000 AAV-293 cells
were
transfected with 1 µg total DNA and different ratios of VP1 insertion
constructs in respect to the Rep/Cap(VP1KO) plasmid were
co-transfected. 72
hours post transfection viruses were harvested and HT1080 and A431
cells were
transduced. 48 hours later the number of transduced, or to be precise
mVenus
positive, cells was determined via flow cytometry (Fig. 17 a, b).</P><P class="MsoNormal"><B>Figure 17 a: Flow cytometry
analysis</B>. Transduced and
therefore mVenus positive HT1080 cells, infected with virus particles
containing different ratios of VP1 insertion constructs in respect to
Rep/Cap(VP1KO) plasmid. </P><P class="MsoNormal"> </P><P class="MsoNormal"><B>Figure 17 b: Flow cytometry
analysis</B>. Transduced and
therefore mVenus positive A431 cells, infected with virus particles
containing
different ratios of VP1 insertion constructs in respect to
Rep/Cap(VP1KO)
plasmid. </P><P class="MsoNormal"> </P><P class="MsoNormal">Again results revealed that all virus
particles remained
infectious, regardless of whether inserting the Affibody or mVenus.
This
indicated that VP1 tolerated larger peptides inserted downstream of its
unique
N-terminal region and that this modification still allowed virus
assembly and
packaging.</P><H3><A name="_Toc275953555">Infectious Titer by qPCR</A></H3><P class="MsoNormal">We transfected 250.000 AAV-293 cells
with 1 µg of total DNA
composed of equal amounts of Rep/Cap, pHelper and vector plasmid. VP2
fusion or
VP1 insertion plasmids were co-transfected with two different ratios in
respect
to Rep/Cap(VP1KO) or Rep/Cap(VP2KO):  25 % VP2 fusion
or VP1 insertion
proteins allow better assembly and packaging of the virus particles,
compared
to 50 % VP2 fusion or VP1 insertion proteins which increase the chance
of 
integration into the capsids. </P><P class="MsoNormal">We created viruses containing the Z<SUB><SPAN style="font-size: 12pt; line-height: 200%;">EGFR:1907</SPAN></SUB>
Affibody fused
to VP2 or inserted into VP1 and the DARPin E01 fused to VP2. These
types of
AAV2 particles were produced in two versions: With or without HSPG
binding
affinity knock down (587KO). </P><P class="MsoNormal">Viruses were harvested three days
post transfection. The genomic
titer was determined via qPCR by amplification of a specific sequence
located
in the CMV promoter of the vector plasmid (Table 3).</P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 100%;">Table 3:
Quantitative Real-Time PCR.</SPAN></B> Determination of
genomic titer. Data
were corrected for negative control value.</P><DIV align="center"><TABLE class="MsoNormalTable" style="border: medium none ; width: 450.2pt; border-collapse: collapse;" border="1" cellpadding="0" cellspacing="0" width="600"><TBODY><TR><TD style="border: 1pt solid windowtext; padding: 2.85pt 5.4pt; background: rgb(234, 241, 221) none repeat scroll 0% 50%; -moz-background-clip: initial; -moz-background-origin: initial; -moz-background-inline-policy: initial; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center; line-height: normal;" align="center"><B><SPAN style="color: black;">Co-transfected
Construct</SPAN></B></P></TD><TD style="border-style: solid solid solid none; border-color: windowtext windowtext windowtext -moz-use-text-color; border-width: 1pt 1pt 1pt medium; padding: 2.85pt 5.4pt; background: rgb(234, 241, 221) none repeat scroll 0% 50%; -moz-background-clip: initial; -moz-background-origin: initial; -moz-background-inline-policy: initial; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center; line-height: normal;" align="center"><B><SPAN style="color: black;">Ratio</SPAN></B></P></TD><TD style="border-style: solid solid solid none; border-color: windowtext windowtext windowtext -moz-use-text-color; border-width: 1pt 1pt 1pt medium; padding: 2.85pt 5.4pt; background: rgb(234, 241, 221) none repeat scroll 0% 50%; -moz-background-clip: initial; -moz-background-origin: initial; -moz-background-inline-policy: initial; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center; line-height: normal;" align="center"><B><SPAN style="color: black;">Genomic
Titer /1ml</SPAN></B></P><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center; line-height: normal;" align="center"><B><SPAN style="color: black;">Corrected
For Negative Control</SPAN></B></P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">Affibody_MiddleLinker_VP2/3</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">25:75</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">2,20E+08</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">Affibody_MiddleLinker_VP2/3</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">50:50</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">2,39E+08</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">Affibody_MiddleLinker_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">25:75</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">1,17E+09</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">Affibody_MiddleLinker_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">50:50</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">5,44E+08</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">CFP_MiddleLinker_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">25:75</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">3,63E+09</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">CFP_MiddleLinker_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">50:50</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">1,67E+09</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">6xHis_MiddleLinker_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">25:75</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">3,37E+09</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">6xHis_MiddleLinker_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">50:50</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">1,38E+09</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">VP1up_NLS_Affibody_VP2/3</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">25:75</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">3,52E+09</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">VP1up_NLS_Affibody_VP2/3</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">50:50</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">1,50E+09</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">VP1up_NLS_Affibody_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">25:75</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">6,98E+08</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">VP1up_NLS_Affibody_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">50:50</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">5,30E+08</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">VP1up_NLS_6xHis_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">25:75</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">5,25E+09</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">VP1up_NLS_6xHis_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">50:50</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">1,65E+09</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">DARPin_MiddleLinker_VP2/3</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">25:75</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">4,36E+08</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">DARPin_MiddleLinker_VP2/3</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">50:50</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">3,93E+08</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">DARPin_MiddleLinker_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">25:75</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">1,00E+09</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">DARPin_MiddleLinker_VP2/3(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">50:50</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">3,99E+08</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">Control: Rep/Cap</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">100%</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">1,55E+08</P></TD></TR><TR><TD style="border-style: none solid solid; border-color: -moz-use-text-color windowtext windowtext; border-width: medium 1pt 1pt; padding: 2.85pt 5.4pt; width: 191.8pt;" width="256"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">Control: Rep/Cap(587KO)</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 110.2pt;" nowrap="nowrap" width="147"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">100%</P></TD><TD style="border-style: none solid solid none; border-color: -moz-use-text-color windowtext windowtext -moz-use-text-color; border-width: medium 1pt 1pt medium; padding: 2.85pt 5.4pt; width: 148.2pt;" nowrap="nowrap" width="198"><P class="MsoNormal" style="margin-bottom: 0.0001pt; text-align: center;" align="center">5,39E+08</P></TD></TR></TBODY></TABLE></DIV><P class="MsoNormal"> </P><P class="MsoNormal">We investigated transduction of
different cell lines. For
this purpose 100.000 HT1080, HeLa or A431 cells were seeded and
transduced with
50 µL virus stock and harvested 24 hours later.  Infectious
titers were
determined via qPCR and normalized to the genomic titers (Fig. 17-19).</P><P class="MsoNormal">Figure 18 shows infection efficacy of
DARPin exposing
viruses. Transduction of HT1080 cells was almost not affected as long
as
binding to HSPG was not knocked down. HeLa cells were also infected
less
efficient compared to the controls. However, A431 cells which
overexpress EGFR
were not infected by the controls. Transduction is rescued by
integration of
the DARPin into the virus capsid. By additionally knocking down the
HSPG
binding affinity these cells are transduced 10 times better, reaching
wild type
capsid HT1080 infection efficacy. These results indicated that specific
re-targeting of AAV2 virus particles towards EGFR over expressing tumor
cells
was achieved by N-terminal fusion of targeting motifs to VP2.</P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 100%;">Figure 18:
DARPin E01 VP2 Fusion.</SPAN></B> Infectious titers were
determined with or
without HSPG knock down for HT1080, HeLa and A431 cells.
Control:Rep/Cap
plasmid with and without HSPG knock down.</P><P class="MsoNormal"> </P><P class="MsoNormal">We additionally obtained similar
results for Affibody
exposing viruses: A431 cell transduction could also be rescued by
capsid
integration of the Affibody. Again infection efficacy was increased by
knocking
down the natural tropism of the AAV2 viruses towards HSPG (Fig. 19).
These data
emphasized the functionality of the VP2 fusion constructs for
specifically
targeting tumor cells for therapeutic or imaging
applications. </P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 200%;">Figure
19:
Affibody Z<SUB>EGFR:1907</SUB> VP2 Fusion.</SPAN></B>
Infectious titers were
determined with or without HSPG knock down for HT1080, HeLa and A431
cells.
Control:Rep/Cap plasmid with and without HSPG knock down.</P><P class="MsoNormal"> </P><P class="MsoNormal">Figure 20 repesents the infectivity
of viruses containing
VP1 inserted Affibody molecules in respect to three different cell
types
(HT1080, HeLa, A431). The data clearly shows that virus capsids
assembled and
remained infectious. These AAV2 particles also featured specific
binding
properties to A431 cells, validating the functionality of  the
VP1 insertion
strategy. The two outlier (HeLa VP1up_NLS_Affibody_VP2/3 25:75
&amp; HT1080
VP1up_NLS_Affibody_VP2/3(587KO) 50:50) should be left unconsidered. </P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 100%;">Figure 20:
Affibody Z<SUB>EGFR:1907</SUB> VP1 Insertion.</SPAN></B>
Infectious titers were
determined for 25:75 and 50:50 transfection ratios with or without HSPG
knock
down for HT1080, HeLa and A431 cells. Control:Rep/Cap plasmid with and
without
HSPG knock down.</P><P class="MsoNormal"> </P><H3><A name="_Toc275953556">Killing cells: Time-Lapse</A></H3><P class="MsoNormal">HT1080 and A431 cells were transduced
with so called
“All-in-One” viruses containing the Affibody Z<SUB><SPAN style="font-size: 12pt; line-height: 200%;">EGFR:1907</SPAN></SUB>
fused to VP2/3(587KO_His-Tag) and
packaged with the guanylate kinase fused to the thymidine kinase coding
sequence (GMK-TK). A time series of pictures was started directly after
adding
20 µM Ganciclovir (Fig.21).</P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 200%;">Figure 21
a: Time-lapse</SPAN></B>. HT1080 (control) cells transduced
with GMK-TK
packaged viruses and treated with 20 µM Ganciclovir A) 0 hours, B) 7
hours, C)
15 hours and D) 23 hours post transduction.</P><P class="MsoNormal"> </P><P class="MsoNormal"><B><SPAN style="font-size: 10pt; line-height: 200%;">Figure 21
b: Time-lapse</SPAN></B>. A431 cells transduced with GMK-TK
packaged viruses
and treated with 20 µM Ganciclovir A) 0 hours, B) 7 hours, C) 15 hours
and D)
23 hours post transduction.</P><P class="MsoNormal"> </P><P class="MsoNormal">Virus and Ganciclovir treatment only
slightly affect the
morphology of HT1080 cells. After 23 hours of incubation in
20µM
Ganciclovir the cells had almost the same appearance as at time point
zero
(Fig. 21 a). In comparison to that A431 epidermoid carcinoma cells were
efficiently killed after transduction and Ganciclovir add-on: After 23
hours
nearly all cells were lysed (Fig. 21 b). These results clearly
demonstrate that
we were able to specifically target EGFR over-expressing tumor cells
via capsid
integrated Affibody and that these transduced cells were efficiently
killed by
expressing the GMK-TK which converted prodrug Ganciclovir into its
cell-toxic monophosphate.
</P><DIV class="printfooter">
Retrieved from &quot;<A href="http://2010.igem.org/Team:Freiburg_Bioware/Project/Targeting_Fusion">http://2010.igem.org/Team:Freiburg_Bioware/Project/Targeting_Fusion</A>&quot;</DIV></DIV></DIV><DIV id="footer-box" class="noprint"><DIV id="footer"><UL id="f-list"><LI id="t-recentchanges"><A href="/Special:RecentChanges" title="Recent changes">Recent changes</A></LI><LI id="t-whatlinkshere"><A href="/Special:WhatLinksHere/Team:Freiburg_Bioware/Project/Targeting_Fusion" title="List of all wiki pages that link here [j]" accesskey="j">What links here</A></LI><LI id="t-recentchangeslinked"><A href="/Special:RecentChangesLinked/Team:Freiburg_Bioware/Project/Targeting_Fusion" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</A></LI><LI id="t-specialpages"><A href="/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</A></LI><LI><A href="/Special:Preferences">My preferences</A></LI></UL></DIV><DIV id="footer"><UL id="f-list"><LI id="t-print"><A href="/wiki/index.php?title=Team:Freiburg_Bioware/Project/Targeting_Fusion&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</A></LI><LI id="t-permalink"><A href="/wiki/index.php?title=Team:Freiburg_Bioware/Project/Targeting_Fusion&amp;oldid=208826" title="Permanent link to this revision of the page">Permanent link</A></LI><LI id="privacy"><A href="/2010.igem.org:Privacy_policy" title="2010.igem.org:Privacy policy">Privacy policy</A></LI><LI id="disclaimer"><A href="/2010.igem.org:General_disclaimer" title="2010.igem.org:General disclaimer">Disclaimers</A></LI></UL></DIV></DIV></DIV></DIV></BODY></HTML>